Clinical Trial Update: Open-Label Hepatic Impairment Study [Phase 1]

View source ↗

Summary

An open-label Phase 1 hepatic impairment study sponsored by Gilead Sciences for Hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED